Return to Article Details
The Clinical Evidence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, Dapaglifozin, a New Pillar of Treatment for Heart Failure with Reduced Ejection Fraction
Download
Download PDF